CD274 and melanoma: Vesicular PD-L1 protein and mRNA copy numbers could be used to monitor the response to pembrolizumab and nivolumab in melanoma and NSCLC: while immunotherapy-unresponsive patients have demonstrated high pre-treatment levels of PD-L1, PD-L1 mRNA declined in responsive patients [114,142].